MYMD-1, a novel alkaloid compound, ameliorates the course of experimental autoimmune encephalomyelitis.

Autor: Glenn JD; Depts of Neurology, Johns Hopkins University School of Medicine, USA., Pantoja IM; Depts of Cellular and Molecular Medicine, Johns Hopkins University School of Medicine, USA., Caturegli P; Depts of Pathology, Johns Hopkins University School of Medicine, USA., Whartenby KA; Depts of Neurology, Johns Hopkins University School of Medicine, USA; Depts of Cellular and Molecular Medicine, Johns Hopkins University School of Medicine, USA; Depts of Oncology, Johns Hopkins University School of Medicine, USA. Electronic address: whartenby@jhmi.edu.

Publikováno v: Journal of neuroimmunology [J Neuroimmunol] 2020 Feb 15; Vol. 339, pp. 577115. Date of Electronic Publication: 2019 Nov 20.